Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy — DC-TC

Primary Hepatocellular Carcinoma Clinical Trial

Official title:
Clinical Study of the Safety of Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy

Status Completed

Clinical Trial Summary

Although liver resection, liver transplantation, a-interferon, Transarterial Chemo Embolization (TACE), percutaneous ethanol injection (PEI), Percutaneous microwave coagulation therapy (PMCT), Radiofrequency ablation (RFA) provide options to treat patients with HCC, the high recurrence rate of mid-late stage liver cancer still exists. The safety of autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma (HCC) Patients Following Resection and TACE Therapy will be evaluated.

Clinical Trial Description

The study is a single center,open label trial. To obtain safety information on toxicities and adverse events attributable to the subcutaneous injections of autologous dendritic cells incubated with irradiated autologous tumor stem cells and suspended in GM-CSF in patients with HCC. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01828762
Study type	Interventional
Source	Cellular Biomedicine Group Ltd.
Contact
Status	Completed
Phase	N/A
Start date	December 2012

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00966251` - Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma	Phase 1/Phase 2
Recruiting	`NCT03614546` - Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma	N/A
Not yet recruiting	`NCT03672305` - Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC	Early Phase 1
Not yet recruiting	`NCT06124001` - Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma	Phase 1/Phase 2
Not yet recruiting	`NCT02956772` - Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients	Phase 2
Active, not recruiting	`NCT01563484` - Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media	Phase 2/Phase 3
Not yet recruiting	`NCT05872841` - H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis	Phase 2
Recruiting	`NCT05242757` - Clinical Study of MAK Immune Cells in the Treatment of PHC	N/A